End-to-End Phytochemical CRO & CDMO Solutions: Integrating Active Ingredient Screening, Pharmacological Assays, Industrial Scale-Up, and Global Regulatory Dossier Compliance.
From validated analytical method protocols to animal pharmacology models, review our qualified technical development lines built for commercial-scale technology transfer.
The worldwide Contract Development and Manufacturing Organization (CDMO) sector is undergoing an epistemological shift from raw toll processing toward integrated phytochemical and biopharmaceutical molecular engineering.
Phytochemical and botanical drug manufacturing requires navigating immense chemical complexity. In Western Europe (EMA), the United States (FDA 21 CFR Part 210/211/111), and East Asia (NMPA), the regulatory oversight applied to natural therapeutic entities has converged with small-molecule pharmaceutical requirements. Cross-batch variability, poly-constituent degradation, and trace pesticide or heavy metal contamination present structural liabilities for sponsor companies that choose purely fragmented manufacturing routes.
A modern Contract Development and Manufacturing Organization (CDMO) does not merely provide cleanroom tank space; it creates structural biological reproducibility. By deploying integrated high-performance thin-layer chromatography (HPTLC), HPLC-MS/MS fingerprinting, and rigorous continuous-flow solvent purification, MedGence solves the historically prohibitive challenge of natural active standardization.
Protecting formulation formulas and customized engineering procedures is the foundation of long-term contract manufacturing partnerships. Operating within strict non-disclosure legal frameworks, proprietary solvent fractions, chromatographic enrichment columns, and downstream dosage configurations remain under full client copyright and patent ownership.
Our contract research and manufacturing protocols are strictly structured around distinct market access thresholds, ensuring your botanical products bypass localized compliance friction.
Tailored specifically for North American (DSHEA) and EU Novel Food regulations. We provide concentrated herbal extracts and micro-encapsulated formulations that achieve targeted organoleptic stability, precise active compound standardization (e.g., total ginsenosides, polyphenols, astragalosides), and verified batch-to-batch organoleptic consistency for capsules, gummies, and functional oral drinks.
Formulated under full cGMP pharmaceutical quality conditions. We execute ICH-compliant stability protocols, validation assays, and comprehensive CMC (Chemistry, Manufacturing, and Controls) dossier generation. Designed for biopharmaceutical firms filing Investigational New Drug (IND) and Botanical New Drug Applications (NDA) requiring preclinical animal safety and Phase I–IV validation.
Engineered to conform with INCI registers, EU Regulation (EC) No 1223/2009, and China CSAR filing standards. We develop solvent-free botanical concentrates, liposomal active delivery vectors, and enzymatic plant extracts with clinical evidence validating anti-inflammatory, antioxidant, melanin-inhibition, and skin barrier-repair biological markers.
Combining geographical agricultural integration with cutting-edge bioprocess infrastructure delivers unparalleled speed, economic scalability, and raw material purity.
China houses more than 11,000 recorded medicinal plant taxa. Our Changsha, Hunan hub maintains direct trace-access to specialized Good Agricultural Practices (GAP) cultivation bases across varied geological and climatic regions—monitoring soil heavy metals, rainfall windows, and diurnal thermal variations to ensure maximum secondary metabolite yields.
Bridging benchtop assays and metric-ton extraction is the primary failure point in botanical contract manufacturing. MedGence features comprehensive 50L to 10,000L dynamic countercurrent extraction vessels, nanofiltration, continuous disc centrifuges, and spray-freeze drying towers that prevent thermal denaturation of delicate active bio-matrices.
Integrated reagent chemical pipelines, in-house mechanical spare fabrication, and dedicated analytical personnel slash R&D turnaround. Projects advance from raw botanical screening and assay creation to commercial pilot verification runs in weeks, saving 40–60% of total time compared to fragmented Western development cycles.
Expanding natural medicine discovery by uniting historical medicinal chemistry with advanced computational design and molecular biotechnology.
Standardizing ultra-performance liquid chromatography (UPLC) multi-wavelength profiles. Quantifying dynamic changes across batch origins and manufacturing thermal gradients to secure multi-target equivalence and batch stability.
Employing machine learning models to map plant poly-molecules against human kinase, GPCR, and enzyme receptors. Predicting compound efficacy and adverse side effects in silico before conducting in vitro and in vivo assays.
Constructing microbial chassis strains (yeast and E. coli) that synthesize ultra-rare plant ginsenosides, cannabinoids, and flavonoids at high yields, bypassing harvesting bottlenecks while protecting wild botanical diversity.
Our quality systems are structured around global regulatory frameworks, supporting seamless export releases and smooth international regulatory inspections.
Complete batch production records (BPR), clean-in-place (CIP) validation, allergen segregations, and full trace documentation tailored for direct cGMP 21 CFR Part 111 / 210/211 facility inspections.
Rigorous testing for residual solvents, polycyclic aromatic hydrocarbons (PAHs), ethylene oxide, and heavy metals conforming directly with strict European Pharmacopoeia botanical monographs.
Unmatched experience in China’s modernized botanical drug regulatory pathways, having secured 56 hospital preparations and guided multiple class-leading TCM drug candidates through national approval.
Equipped with 21 CFR Part 11 electronic data capture, computerized audit trails, climate-controlled retention chambers, and ISO/IEC 17025 accredited analytical routines.
Our contract research and extraction programs power top healthcare corporations and academic medical centers.
Beijing Tongrentang Group
China Resources Sanjiu Medical
Sunflower Pharmaceutical Group
Livzon Pharmaceutical Group
Dihon Pharmaceutical Group
Golden Throat Holdings Group
Yangtzi River Pharmaceutical Group
Humanwell Healthcare Group
Answers to essential questions covering batch validation, intellectual property containment, pilot scale-up, and analytical transfer.
Select a specialized contract manufacturing division below to initiate your technical brief, analytical consultation, and pilot run schedule.
